Skip to main content
康乐卫士 logo

康乐卫士 — Investor Relations & Filings

Ticker · 920575 ISIN · CNE1000059W8 Beijing Stock Exchange Manufacturing
Open in API
Filings indexed 537 across all filing types
Latest filing 2024-03-21 Board/Management Inform…
Country CN China
Listing Beijing Stock Exchange 920575

About 康乐卫士

https://www.klws.com/

Beijing Health Guard Biotechnology Inc. is a clinical-stage biopharmaceutical company specializing in the research, development, and commercialization of innovative recombinant human vaccines. The company leverages advanced structural biology and protein engineering platforms to create a diverse pipeline of vaccine candidates. Its primary focus includes the development of high-valent human papillomavirus (HPV) vaccines, with its trivalent and nine-valent candidates in late-stage clinical trials. Additionally, the company is advancing candidates for respiratory syncytial virus (RSV), shingles, and other infectious diseases. By utilizing recombinant protein technology, Health Guard aims to provide high-quality, affordable immunization solutions to address significant unmet medical needs. Its technical expertise encompasses antigen design, high-throughput screening, and large-scale manufacturing processes.

Recent filings

Filing Released Lang Actions
董事会关于独立董事2023年度独立性情况的专项意见
Board/Management Information Classification · 95% confidence The document is a board announcement regarding the independence of the company's independent directors for the year 2023. It references compliance with regulatory guidelines on independent directors and confirms no conflicts of interest. There is no financial data, no mention of financial results, no shareholder voting results, no meeting materials, and no report publication. The content is focused on board/management information about director independence. Therefore, the document fits best under Board/Management Information (MANG). The document length is short and it is a formal announcement by the board, not a report or presentation.
2024-03-21 Chinese
2023年年度报告
Annual Report Classification · 100% confidence The document is titled '年度报告' which translates to 'Annual Report' and covers the fiscal year 2023. It includes detailed sections such as company overview, financial data and accounting indicators, management discussion and analysis, major events, shareholder information, financing and profit distribution, board and senior management information, industry information, corporate governance, internal control, investor protection, and financial accounting reports. The document contains comprehensive financial data, management analysis, risk factors, and detailed accounting data. It also mentions an unqualified audit opinion from Ernst & Young Hua Ming LLP, indicating it is a full audited annual report. The length of the document (15,000 characters) and the depth of content confirm it is the full annual report rather than an announcement or summary. Therefore, the document fits the definition of an Annual Report (10-K). FY 2023
2024-03-21 Chinese
2023年度独立董事述职报告（李晓静）
Board/Management Information Classification · 95% confidence The document is titled as an "Independent Director's Annual Report" for the year 2023 by an independent director of Beijing Kangle Weishi Biotechnology Co., Ltd. It details the director's background, attendance at board and committee meetings, independent opinions on various company matters, communication with auditors and shareholders, and overall evaluation and suggestions for the company. The content is a detailed report on the independent director's duties and activities during the year, which is a form of management or board-related information rather than a financial report or announcement. It is not an annual report (10-K), audit report (AR), or earnings release (ER). It is not a short announcement or certification but a substantive report on board/management activities and governance. Therefore, the most appropriate classification is Board/Management Information (MANG). The document length (4848 characters) supports it being a full report rather than a brief announcement.
2024-03-21 Chinese
第四届监事会第二十九次会议决议公告
Regulatory Filings Classification · 95% confidence The document is a detailed announcement of resolutions passed at the 29th meeting of the 4th Supervisory Board of Beijing Kangle Weishi Biotechnology Co., Ltd. It includes multiple agenda items such as approval of the 2023 Supervisory Board Work Report, 2023 Annual Report and its summary, 2023 Financial Final Report, 2024 Financial Budget Report, 2023 Audit Report, and other special reports. The document repeatedly states that these reports are disclosed on the Beijing Stock Exchange information disclosure platform and that these resolutions will be submitted to the shareholders' meeting for approval. The document itself does not contain the full annual report or financial statements but rather the meeting resolutions approving these reports and referring to their publication elsewhere. The document length is under 5,000 characters and serves as a formal meeting resolution announcement rather than the full annual report or audit report. According to the "Menu vs Meal" rule, this is an announcement of meeting resolutions and report approvals, not the reports themselves. Therefore, the best classification is Regulatory Filings (RNS), as it is a regulatory announcement of supervisory board meeting resolutions and approvals of various reports.
2024-03-21 Chinese
北京康乐卫士生物技术股份有限公司2023年度募集资金存放与实际使用情况鉴证报告
Regulatory Filings
2024-03-21 Chinese
2023年度独立董事述职报告（韩强）
Board/Management Information Classification · 95% confidence The document is titled as an "Independent Director's Annual Work Report" for the year 2023 from Beijing Kangle Weishi Biotechnology Co., Ltd. It details the independent director's background, attendance at board and committee meetings, opinions on company matters, and overall evaluation of their duties during the year. The content focuses on governance, director activities, and compliance with laws and regulations. It does not contain financial statements or financial performance data. It is a report on board/management information specifically related to the independent director's duties and opinions. Therefore, the most appropriate classification is Board/Management Information (MANG). The document length is 3240 characters, which is relatively short but contains substantive content about board activities rather than just an announcement or certification, so it is not RPA or RNS.
2024-03-21 Chinese

Browse filings by year

4 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.